カテゴリ： GlobalData, アメリカ, 企業調査

Exelixis Inc (EXEL)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Exelixis Inc (EXEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012245
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：118
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Exelixis Inc (Exelixis) is a biopharmaceutical company focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma; and Cotellic (cobimetinib) is developed in combination with vemurafenib for the treatment of patients with mutation-positive advanced melanoma. The company also enters into collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US.

Exelixis Inc (EXEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Exelixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Exelixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Exelixis Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Exelixis Enters into Agreement with Roche 12
Exelixis Enters into Agreement with Bristol-Myers Squibb 13
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 14
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 16
Licensing Agreements 18
Takeda Pharma Enters into Licensing Agreement with Exelixis 18
Ipsen Amends Licensing Agreement with Exelixis 19
Exelixis Enters Into Licensing Agreement With Merck For PI3K-delta 20
Equity Offering 21
Exelixis Raises USD155 Million in Public Offering of Shares 21
Exelixis Completes Public Offering Of Shares For US$80 Million 22
Exelixis Completes Public Offering Of Common Stock For US$147 Million 23
Exelixis Completes Public Offering Of Common Stock For US$69 Million 24
Exelixis Completes An Underwritten Public Offering For US$190 Million 26
Debt Offering 28
Exelixis Completes Public Offering Of Senior Convertible Notes Due 2019 For US$288 Million 28
Exelixis Inc – Key Competitors 30
Exelixis Inc – Key Employees 31
Exelixis Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 01, 2017: Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update 33
Aug 02, 2017: Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update 36
May 01, 2017: Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update 39
Feb 27, 2017: Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 42
Nov 03, 2016: Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update 46
Aug 03, 2016: Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update 49
May 04, 2016: Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update 52
Feb 29, 2016: Exelixis Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 55
Corporate Communications 58
Sep 26, 2016: Exelixis Elects Julie Anne Smith to Its Board of Directors 58
Legal and Regulatory 59
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 59
Product News 60
12/07/2016: Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline 60
10/16/2017: Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma 61
09/20/2016: Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress 63
09/14/2016: European Commission Approves Ipsens Cabometyx (Cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma In Adults Following Prior Vascular Endothelial Growth Factor (Vegf)-Targeted Therapy 64
07/22/2016: Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy 66
04/20/2016: Exelixis Announces Presentation On Cabozantinib At 2016 ASCO Annual Meeting 68
Product Approvals 70
Sep 08, 2017: Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults 70
Aug 16, 2017: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX for the Treatment of Previously Untreated Advanced Kidney Cancer 72
Jul 10, 2017: Kidney Cancer UK delighted NICE recommends cabozantinib on NHS for kidney cancer patients 74
Jul 10, 2017: Life-extending tablet for advanced kidney cancer, Cabometyx (cabozantinib), approved by NICE for routine access by English and Welsh patients 75
Jun 12, 2017: Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer 76
Mar 06, 2017: Exelixis’ Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma 77
Jan 28, 2016: Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma 78
Jan 28, 2016: Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma 79
Jan 11, 2016: Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma 80
Clinical Trials 81
Nov 21, 2017: Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium 81
Oct 16, 2017: Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma 82
Oct 16, 2017: Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma 84
Sep 09, 2017: Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 85
Sep 06, 2017: Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress 87
Sep 04, 2017: Ipsen To Present 7 Abstracts on Cabometyx at European Society of Medical Oncology congress 88
Aug 01, 2017: Exelixis to Feature Presentations on Cabozantinib at ESMO 2017 Congress 90
Jun 19, 2017: Ipsen and its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma 93
Jun 12, 2017: Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors 94
Jun 01, 2017: Ipsen To Present New Data of Cabometyx at ASCO 95
Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors 97
Oct 10, 2016: Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016 99
Oct 07, 2016: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors 101
Sep 27, 2016: Ipsen Announces Data Presentations of Cabozantinib (Cabometyx) at the European Society for Medical Oncology (ESMO) 2016 Congress 102
Sep 06, 2016: Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma 104
Aug 31, 2016: Exelixis presents cabozantinib data at the ESMO 2016 Congress 105
Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO 107
May 23, 2016: Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma 109
Apr 25, 2016: Exelixis Announces FDA Approval of CABOMETYX (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy 111
Feb 01, 2016: Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma 113
Jan 04, 2016: Exelixis Announces Positive Results From Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma to be Presented at ASCO 2016 Genitourinary Cancers Symposium 115
Other Significant Developments 117
Sep 07, 2017: Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy 117
Appendix 118
Methodology 118
About GlobalData 118
Contact Us 118
Disclaimer 118

List of Tables
Exelixis Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Exelixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Exelixis Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Exelixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Exelixis Enters into Agreement with Roche 12
Exelixis Enters into Agreement with Bristol-Myers Squibb 13
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 14
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 16
Takeda Pharma Enters into Licensing Agreement with Exelixis 18
Ipsen Amends Licensing Agreement with Exelixis 19
Exelixis Enters Into Licensing Agreement With Merck For PI3K-delta 20
Exelixis Raises USD155 Million in Public Offering of Shares 21
Exelixis Completes Public Offering Of Shares For US$80 Million 22
Exelixis Completes Public Offering Of Common Stock For US$147 Million 23
Exelixis Completes Public Offering Of Common Stock For US$69 Million 24
Exelixis Completes An Underwritten Public Offering For US$190 Million 26
Exelixis Completes Public Offering Of Senior Convertible Notes Due 2019 For US$288 Million 28
Exelixis Inc, Key Competitors 30
Exelixis Inc, Key Employees 31
Exelixis Inc, Subsidiaries 32

★海外企業調査レポート[Exelixis Inc (EXEL)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Rongsheng Petrochemical Co Ltd (002493)：企業の財務・戦略的SWOT分析
    Summary Rongsheng Petrochemical Co Ltd (Rongsheng), a subsidiary of Zhejiang Rongsheng Holding Group Co Ltd is a chemical company that produces and distributes PTA, polyester fiber and chemical products. The company’s products include synthetic fibers and films, synthetic raw material, synthetic res …
  • RRB Energy Ltd：企業の戦略的SWOT分析
    RRB Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Bio-Rad Laboratories Inc (BIO)-製薬・医療分野：企業M&A・提携分析
    Summary Bio-Rad Laboratories Inc (Bio-Rad) develops and manufactures specialty chemicals for use in biochemical, pharmaceutical and other life science research applications. The company offers a comprehensive range of reagents, apparatus, laboratory instruments, test systems, informatics systems, te …
  • Naia Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Naia Ltd (Naia) is a funding and developing company that address regional and global medical needs. The company develops and manufactures therapeutics for metabolic and rare diseases. It provides global drug development through funding, clinical development, organizational structure and regu …
  • Oncomatryx Biopharma SL：製薬・医療：M&Aディール及び事業提携情報
    Summary Oncomatryx Biopharma SL (Oncomatryx) is a developer of precision drugs. The company offers precision drugs that targets proteins located in the tumor environment. It develops therapeutic antibody-drug conjugates, antibodies, and human-derived proteins, which targets tumor associated stroma. …
  • All in West! Capital Corporation：企業の戦略・SWOT・財務情報
    All in West! Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary All in West! Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Shanghai Pharmaceutical Co Ltd (601607)：企業の財務・戦略的SWOT分析
    Shanghai Pharmaceutical Co Ltd (601607) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Emlin Cosmetics：企業の戦略・SWOT・財務情報
    Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report Summary Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • NaviNet Inc：企業の戦略的SWOT分析
    NaviNet Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • PDL Biopharma, Inc.：企業の戦略・SWOT・財務情報
    PDL Biopharma, Inc. - Strategy, SWOT and Corporate Finance Report Summary PDL Biopharma, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • CSL Limited：企業のM&A・事業提携・投資動向
    CSL Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CSL Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • BioStar Pharmaceuticals Inc (BSPM)：企業の財務・戦略的SWOT分析
    Summary BioStar Pharmaceuticals Inc (BioStar) is a developer, manufacturer and marketer of pharmaceutical and healthcare supplement products for various diseases and conditions. The company offers products such as huangyangning tablets, hyperthyroidism capsules, danshen granule, aoxing oleanolic aci …
  • OPTIMA packaging group GmbH：戦略・SWOT・企業財務分析
    OPTIMA packaging group GmbH - Strategy, SWOT and Corporate Finance Report Summary OPTIMA packaging group GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • A1M Pharma AB：製薬・医療：M&Aディール及び事業提携情報
    Summary A1M Pharma AB (A1M Pharma) is a developer of a medical application for the diagnosis and treatment of pre-eclampsia and acute renal damage. The company develops and commercializes drug candidate for the diagnosis and treatment of pre-eclampsia (pandemic poisoning) and acute renal injury. It …
  • PLx Pharma Inc (PLXP)-製薬・医療分野：企業M&A・提携分析
    Summary PLx Pharma Inc (PLx Pharma) is a drug development company that develops patent-protected delivery systems. The company’s products include PLxGuard delivery system, PLxGuard pipeline products, PL2200 aspirin and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system are used in en …
  • TDC A/S：企業の戦略・SWOT・財務情報
    TDC A/S - Strategy, SWOT and Corporate Finance Report Summary TDC A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Kuros Biosciences AG (KURN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as we …
  • Biscayne Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析
    Summary Biscayne Pharmaceuticals Inc (Biscayne) is a clinical stage biotechnology company that conducts research and development services. The company conducts research and development of therapies based on growth hormone-releasing hormone analogs. Its technology concentrates on a platform of synthe …
  • Hexion Inc.：企業の戦略・SWOT・財務情報
    Hexion Inc. - Strategy, SWOT and Corporate Finance Report Summary Hexion Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • XCMG Construction Machinery Co Ltd：企業の戦略・SWOT・財務分析
    XCMG Construction Machinery Co Ltd - Strategy, SWOT and Corporate Finance Report Summary XCMG Construction Machinery Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆